Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study)

Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch Unique Embedded Aortic Triple-branch Arch Stent Graft System (GENIUS Study)

A prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Tribranch Embedded Aortic Triple-branch Arch Stent Graft System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for true/pseudo aortic arch aneurysms and ulcers involving aortic arch . (GENIUS Study)

Study Overview

• Status: Recruiting
• Conditions: Aortic Arch Aneurysm
• Intervention / Treatment: Device: WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system

Detailed Description

This study is a prospective ,multiple center study about the safety and efficacy of WeFlow-Tribranch Embedded Aortic Triple-branch Arch Stent Graft System , it is expected to complete the implantation of 90 patients in 20 centers within 20 months, and interim follow-up was conducted before discharge, 30 days after surgery, 6 months after surgery and 12 months after surgery, long-term follow-up will be performed at 24th month, 36th month, 48th month and 60th month postoperatively.

• Study Type: Interventional
• Enrollment (Estimated): 90
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Wei Guo; Phone Number: 13910758706; Email: Pla301dml@vip.sina.com

Study Locations

• China
  • Beijing, China
    • Recruiting
    • Beijing Anzhen Hospital, Capital Medical University
    • Contact: Zhong Chen
  • Beijing, China
    • Recruiting
    • Chinese PLA Gencral Hosptial
    • Contact: Wei Guo; Phone Number: 13910758706
  • Changchun, China
    • Recruiting
    • The First Hospital of Jilin University
    • Contact: Yongsheng Gao
  • Changsha, China
    • Recruiting
    • Xiangya Hospital of Central South University
    • Contact: Wei Wang
  • Chengdu, China
    • Recruiting
    • West China Hospital of Sichuan University
    • Contact: Jia Hu
  • Guangzhou, China
    • Recruiting
    • Guangdong Provincial Hospital of Traditional Chinese Medicine
    • Contact: Xiaoping Fan
  • Guangzhou, China
    • Recruiting
    • The First Affiliated Hospital ,Sun Yat-sen University
    • Contact: Guangqi Chang
  • Harbin, China
    • Recruiting
    • The First Affiliated Hospital of Harbin Medical University
    • Contact: Baodong Xie
  • Jinan, China
    • Recruiting
    • Shandong Provincial Hospital
    • Contact: Xuejun Wu
  • Kunming, China
    • Recruiting
    • The First People's Hospital of Yunnan Province
    • Contact: Kunmei Gong
  • Nanchang, China
    • Recruiting
    • The Second Affiliated Hospital of Nanchang University
    • Contact: Weimin Zhou
  • Nanjing, China
    • Recruiting
    • The First Affiliated Hospital of Nanjing Medical University
    • Contact: Yongfeng Shao
  • Nanjing, China
    • Recruiting
    • Nanjing First Hospital
    • Contact: Xin Chen
  • Qingdao, China
    • Recruiting
    • The Affiliated Hospital of Qingdao University
    • Contact: Mingjin Guo
  • Shanghai, China
    • Recruiting
    • Shanghai Chest Hospital
    • Contact: Dan Zhu
  • Shanghai, China
    • Recruiting
    • Zhongshan Hospital, Fudan University
    • Contact: Weiguo Fu
  • Shenyang, China
    • Recruiting
    • The First Affiliated Hospital of China Medical University
    • Contact: Shijie Xin
  • Xi'an, China
    • Recruiting
    • The First Affiliated Hospital of PLA Air Force Military Medical University
    • Contact: Jian Zuo
  • Xiamen, China
    • Recruiting
    • Xiamen Cardiovascular Hospital
    • Contact: Xijie Wu
  • Zhengzhou, China
    • Recruiting
    • First Affiliated Hospital of Zhengzhou University
    • Contact: Zhen Li

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients aged 18 to 80 years old;
2. Diagnosed with aortic arch lesions requiring intervention, including true aortic arch aneurysms, pseudo-aortic arch aneurysms, and ulcers involving the aortic arch;

3. Showing a suitable vascular condition, including:

   • Ascending aorta length greater than 50 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery).
   • Ascending aorta diameter ≥ 24 mm and ≤ 48 mm;
   • Proximal anchoring zone length ≥ 30 mm;
   • Branch arteries to be reconstructed were ≤ 24 mm and ≥ 6 mm in diameter and ≥ 20 mm in length;
   • Suitable arterial access for endovascular interventional treatment;
4. Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the patient him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol.
5. Subjects were assessed as high risk for surgery by at least two investigators or judged to have significant surgical contraindications. Recommended reference criteria were a European system for cardiac operative risk evaluation (EuroScore) score of 6 or higher or other surgical risk factors as judged by the physician team.

Exclusion Criteria:

1. Experienced systemic infection during past three months;
2. Neck surgery was performed within 3 months;
3. Previous endovascular interventional treatment involving the aortic arch was performed;
4. Infectious aortic disease, Takayasu arteritis, Marfan syndrome (or other connective tissue diseases );
5. Severe stenosis, calcification, thrombosis, or tortuosity of the branch artery to be reconstructed;
6. Heart transplant;
7. Suffered Myocardial Infarction or Stroke during past three months;
8. Class IV heart function (NYHA classification);
9. Active peptic ulcers or upper gastrointestinal bleeding occurring within the previous three months;
10. Hematological abnormality, defined as follows: Leukopenia (WBC < 3 ×109/L), acute anemia (Hb < 90 g/L), Coagulation disorders, thrombocytopenia (PLT count < 50 × 109/L);
11. Renal insufficiency, creatinine > 150 umol/L and/or end-stage renal disease requiring renal dialysis;
12. Pregnant or breastfeeding;
13. Allergies to contrast agents;
14. Life expectancy of less than 12 months;
15. Participating in another drug or device research;
16. Any other disease or abnormality that the investigators believe may hinder endovascular interventional treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system; Participants will be treated with WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system	Device: WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system; The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of all-cause mortality and major stroke within 12 months after surgery	All-cause mortality includes cardiac mortality, non-cardiac mortality, and mortality from unknown causes. Severe stroke is defined as a modified Rankin score (mRS) ≥ 2 at 90 days following stroke onset.	12 months after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of immediate technical success following surgery	Immediate technical success is defined as successful delivery of the aortic and branching stent graft conveyors to their predetermined positions, accurate positioning and successful deployment of the stent, safe removal of the delivery device outside the body, and the absence of Type I and III endoleaks and all branching stents patency per imaging studies conducted at the end of the procedure .	immediately after the surgery
Rate of aortic aneurysm progression under control	Aortic aneurysm progression under control is defined as maximum increase in the diameter of the aortic aneurysm was ≤ 5 mm when compared with preoperative aortic aneurysm as of a 12-month postoperative CTA review.	12 months after operation
Incidence of Type I or Type III endoleak	Endoleak detected by DSA or CTA during operation and at 1, 6, and 12 months after operation. Intraoperative endoleaks subject to adjuvant treatment are not recorded. Endoleaks occurring after the completion of the procedure followed by one or more endoleaks occurring in the same subject at different follow-up stages that were not treated are counted as a single instance.	during operation and at 1, 6, and 12 months after operation
Incidence of aortic covered stent graft displacement	CTA examination will be performed at 6 months, and 12 months after operation to determine if the stent has migrated, and evaluations will be recorded for both the main and branch stents. Displacement is defined as a nodal aortic or branching stent graft displacement of more than 10 mm compared with that at postoperative day 30.	6 months, 12 months after operation
Postoperative branch vessel patency rate	CTA examinations will be performed at 1 month, 6 months, and 12 months after operation to evaluate branch vessel reconstruction and assess for occlusion, stenosis, or in-stent thrombosis.	1 month, 6 months, 12 months after operation
Rate of conversion to thoracotomy or secondary intervention	Whether or not the patient experienced surgically induced de novo aortic dissection converted to thoracotomy or secondary intervention will be determined.	30 days, 6 months, and 12 months after operation
Rate of major adverse events	Refers to all-cause mortality, myocardial infarction, ischemic stroke, or respiratory failure occurring within 30 days after surgery. More specifically, myocardial infarction refers to a drastic reduction or complete interruption of the coronary blood supply due to coronary artery disease, resulting in severe and prolonged acute ischemia of the corresponding myocardium, leading to necrosis of cardiomyocytes. Ischemic stroke refers to the result of necrosis of brain tissue caused by narrowing or occlusion of the arteries supplying blood to the brain or insufficient blood supply to the brain. Respiratory failure is defined as a state resulting in significantly prolonged intubation, tracheotomy, deterioration of lung function, or other fatal outcomes.	30 days after surgery
Rate of aortic aneurysm-related mortality	Death due to aortic aneurysm rupture or endovascular treatment.	12 months after operation
Incidence of severe adverse events	Refers to an event that occurs during the clinical trial that results in mortality or serious deterioration in patient health, including a fatal illness or injury, a permanent defect in body structure or body function, or an event that requires medical or surgical intervention to avoid permanent defects in body structure or body function.	30 days, 6 months, and 12 months after operation
Incidence of device-related adverse events	Device-related adverse events refer to an adverse medical event related to the use of a device that occurs during the clinical trial. However, a distinction should be made with respect to normal postoperative stress response, such as fever and chest and back discomfort, which, in the judgment of the investigator, need not be recorded as an adverse event. Recording of device-related adverse events will be applicable for conditions that are deemed by the investigator to be definitely related, possibly related to the test device.	30 days, 6 months, and 12 months after operation

Collaborators and Investigators

• Sponsor: Hangzhou Endonom Medtech Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2024
• Primary Completion (Actual): December 31, 2025
• Study Completion (Estimated): December 31, 2030

Study Registration Dates

• First Submitted: April 22, 2024
• First Submitted That Met QC Criteria: April 22, 2024
• First Posted (Actual): April 26, 2024

Study Record Updates

• Last Update Posted (Actual): May 1, 2026
• Last Update Submitted That Met QC Criteria: April 27, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Aortic Diseases; Aneurysm; Aortic Aneurysm; Aortic Aneurysm, Thoracic; Aneurysm, Aortic Arch
• Other Study ID Numbers: WQ21-2301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data will be shared for scientific purposes after the completion of the clinical trial. However, patients' electronic records and any CTA files are outside the scope of our data sharing policy. Researchers wanting to request data can submit a detailed application to the investigators. Data will be released depending on the scientific quality of the submitted request.
• IPD Sharing Time Frame: It is expected that data will be obtained after study completion for at least one year.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No